Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc12.2 | Oral Communications 12: Reproductive and Developmental Endocrinology | ECE2022

Genetic cause of POI are common, the case for next generation sequencing?

Vogt Elinor , Bratland Eirik , Husebye Eystein Sverre , Bjornsdottir Sigridur , Berland Siren , Oksnes Marianne

Context: Premature ovarian insufficiency (POI) affects approximately 1-3% of women. Clinical presentations are heterogeneous and the underlying etiologies remain unknown in the majority of cases.Objective/aim: To characterize presentations of POI and to evaluate the distribution of underlying etiologies in women with newly diagnosed POI of unknown cause.Design: Prospective study of 100 women with newly diagnosed POI. Autoimmunity w...

ea0032p9 | Adrenal cortex | ECE2013

Insulin sensitivity in patients with Addison's disease: a randomised cross-over trial comparing conventional glucocorticoid replacement therapy with continuous subcutaneous hydrocortisone infusion therapy.

Bjornsdottir Sigridur , Nystrom Thomas , Isaksson Magnus , Oksnes Marianne , Husebye Eystein , Lovas Kristian , Kampe Olle , Hulting Anna Lena , Bensing Sophie

Background: Conventional glucocorticoid replacement therapies result in unphysiological variation in plasma cortisol levels; concern has been raised regarding long-term metabolic consequences. Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), which can mimic the normal diurnal cortisol rhythm. The aim of this study was to compare insulin sensitivity in patients with AddisonÂ’s disease (AD) on CSHI vs three daily d...

ea0035p33 | Adrenal cortex | ECE2014

Circadian cortisol and GH profiles in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy

Oksnes Marianne , Bjornsdottir Sigridur , Isaksson Magnus , Methlie Paal , Nilsen Roy , Kampe Olle , Hulting Anna-Lena , Husebye Eystein , Lovas Kristian , Nystrom Thomas , Bensing Sophie

Background: Conventional glucocorticoid replacement therapy in patients with AddisonÂ’s disease (AD) is unphysiological with possible adverse effects on mortality, morbidity and quality of life. Physiological amounts of glucocorticoids are required for normal GH production and release and a chronically raised cortisol level, suppresses the secretion of GH with possible metabolic and cardiovascular consequences. The diurnal cortisol profile can likely be restored by continu...